Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Phase 3 Completed
1,099 enrolled
ANGLeD
Phase 3 Unknown
150 enrolled
CASA
Phase 3 Terminated
77 enrolled
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Phase 3 Completed
429 enrolled
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
Phase 3 Completed
2,011 enrolled
TACT2
Phase 3 Unknown
4,400 enrolled
ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment
Phase 3 Completed
300 enrolled
22-00
Phase 3 Completed
1,086 enrolled 10 charts
Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
Phase 3 Completed
720 enrolled
Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer
Phase 3 Completed
2,000 enrolled
Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer
Phase 3 Completed
2,250 enrolled
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
Phase 3 Completed
2,000 enrolled
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
Phase 3 Completed
1,000 enrolled
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
Phase 3 Completed
1,000 enrolled
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
Phase 3 Completed
600 enrolled
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
Phase 3 Unknown
300 enrolled
Chemotherapy Plus Surgery in Treating Women With Breast Cancer
Phase 3 Completed
450 enrolled
Combination Chemotherapy in Treating Women With Stage III Breast Cancer
Phase 3 Suspended
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
Phase 3 Unknown
800 enrolled
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
Phase 3 Completed
280 enrolled
15-95
Phase 3 Completed
344 enrolled
The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
Phase 3 Completed
680 enrolled
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
Phase 3 Completed
150 enrolled
Study of Docetaxel in Breast Cancer Patients
Phase 3 Completed
998 enrolled